Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06364722
Other study ID # ZYS2024-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2015
Est. completion date March 28, 2024

Study information

Verified date March 2024
Source Shanghai Institute of Acupuncture, Moxibustion and Meridian
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multidisciplinary techniques such as multimodal neuroimaging, microbiology, and bioinformatics were applied to study the differences in correlation characteristics between gut microbes, functional brain networks, and peripheral inflammation among patients with active Crohn's disease (CD), CD in remission, and healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date March 28, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 16 Years to 75 Years
Eligibility Inclusion Criteria: 1. 18 = age = 75 years, gender is not limited; 2. Disease in mildly or moderately active stage: 150 = CDAI < 450 and at least one of the following is met: serum C-reactive protein = 5 mg/L, faecal calreticulin = 250 µg/g, or endoscopic ulceration, or remission stage: CDAI < 150 and at least one of the following is met: serum C-reactive protein < 5 mg/L, faecal calreticulin < 250 µg/g, or endoscopic No ulcers; 3. Not taking or taking the following medications: mesalazine (=4 g/d and have been taking for =1 month), prednisone (=15 mg/d and have been taking for =1 month), and/or azathioprine (=1 mg/kg/d and have been taking for =3 months); 4. Those who have not used biologics within 3 months prior to study entry; 5. Those who have never received acupuncture treatment; 6. Understand, agree to participate in the study and sign an informed consent form. Exclusion Criteria: 1. Patients who have recently prepared for pregnancy or are pregnant or breastfeeding; 2. Patients with severe organic pathology; 3. Patients with confirmed psychosis; 4. Patients who are suffering from multiple diseases at the same time and taking other drugs for a long time which may affect the observation of this clinical trial; 5. Patients with severe extra-intestinal manifestations such as severe skin diseases (e.g., erythema nodosum, gangrenous pyoderma, etc.), ocular lesions (e.g., iritis, uveitis, etc.), and thromboembolic diseases; 6. Those with severe intestinal fistulae, abdominal abscesses, intestinal stenosis and intestinal obstruction, perianal lesions (perianal abscesses, etc.), gastrointestinal haemorrhage, intestinal perforation and other complications; 7. Those suffering from short bowel syndrome, those who have undergone abdominal or gastrointestinal surgery within the last six months; 8. Those who are unable to perform acupuncture due to the presence of skin diseases or defects in the area selected for acupuncture.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Acupuncture treatment
We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
Sham acupuncture
Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Institute of Acupuncture, Moxibustion and Meridian Fudan University

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Acupuncture on Crohn's Disease Activity Index (CDAI) Difference in Crohn's Disease Activity Index (CDAI) from baseline at 12 weeks was used for between-group assessment. Week 12
Secondary Effects of Acupuncture on Anxiety and Depression Differences in Hospital Anxiety Depression Scale (HADS) scores from baseline at 12 weeks were used for between-group assessment. Week 12
Secondary Effects of Acupuncture on Quality of Life Differences in Inflammatory Bowel Disease Questionnaire (IBDQ) scores from baseline at 12 weeks were used for between-group assessment. Week 12
Secondary Effect of acupuncture on intestinal inflammation Differences in serum C-reactive protein levels and faecal calprotectin levels from baseline at 12 weeks were used for between-group assessment. Week 12
Secondary Effects of acupuncture on gut microbiota This includes the alpha and beta diversity of gut microbes and the abundance of flora at each level. Week 12
Secondary Effects of acupuncture on the functional activity of brain networks Including brain network graph theory properties, connection strength. Week 12
Secondary Effects of acupuncture on intestinal inflammation Including intestinal barrier function, peripheral Th1/Th17-related inflammatory factors. Week 12
Secondary Effect of Acupuncture on Brain Imaging-Gut Microbiological Correlations The effect of acupuncture was observed by constructing correlations between brain imaging parameters and gut microbiology and gut inflammation levels. Week 12
Secondary Safety evaluation (number of participants with abnormal reactions to acupuncture and moxibustion treatment) Abnormal reactions after acupuncture and moxibustion, such as bleeding, hematoma, scald, dizziness and other phenomena. Week 12
Secondary Safety evaluation (number of participants with abnormal routine blood tests) Routine blood tests, which mainly include the number of red blood cells, white blood cells and platelets per litre of blood. Week 12
Secondary Safety evaluation (number of participants with abnormal Liver function tests) Liver function tests, mainly including peripheral blood concentrations of alanine aminotransferase (U/L), glutamine aminotransferase (U/L), gamma-glutamyl transpeptidase (U/L), alkaline phosphatase (U/L), total bilirubin (µmol/L), direct bilirubin (µmol/L), indirect bilirubin (µmol/L), total protein (g/L), albumin (g/L) and globulin (g/L). Week 12
Secondary Safety evaluation (number of participants with abnormal Renal function tests) Renal function tests, mainly including tests of creatinine (µmol/L) and urea nitrogen (mmol/L) concentrations in peripheral blood. Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT05294107 - Intestinal Organoids N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3